Loading patent…
AssigneeReprise Pharmaceuticals, Inc.
InventorsManuel Friese, Benjamin Schattling, Karin Steinbach, Marc Freichel, Veit Flockerzi, Rudi Vennekens, Doron Merkler
Estimating the term…
The invention relates to a compound which is effective in inhibiting the function of the TRPM4 ion channel and the use of such compound in treating or preventing a neurodegenerative disease, such as Multiple Sclerosis, Parkinson's disease, Alzheimer's disease, or amyotrophic lateral sclerosis, in a subject. The invention also provides a pharmaceutical composition comprising a TRPM4 inhibitory compound. The invention further relates to in vitro methods for identifying pharmaceutically active compounds that are useful for treating or preventing a neurodegenerative disease.
A method of treating multiple sclerosis in a subject in need of treatment thereof, the method comprising administering to the subject a therapeutically effective amount of glibenclamide or a pharmaceutically acceptable salt, solvate or tautomer thereof.
Dependencies are inferred from the claim text.